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   Cisplatin was administered to eleven palients bearing urogenital malignancies tQ evaluate clinical
eMcacy．
（1） ln gesticular tumor cases combination therapy with cisplatin， bleomycin and vinblastine was
   yery effective teSultin’g in 1000／． eMeacy r’atg． Effect of this combination regimen was noticed
   in every tumor of germ cell origin and malignant interstitial ce］1 tumor suggesting wide anti－tumor
   spectrum o．f this ；egimen．
（2） EMcacy of cisplatip against prbstatic cancer was noticed only in 250／． of cases by single adminis－
   tration of this drug． Therefore， combination with anti－androgen’ therapy or other anti－cancer
   chemotherapeutics shouid be considered．
（3）EMcacy ofsingle administration of cisplatin was noticed in no case ofuroepithelial tu皿ors． There」
   fore， radiation therapy and other anti－cancer drugs should be combined to obtain anti－tumor
   effect against malignancies of uroepithelial origin．
（4） Renal toxicity and ototoxicity could be avoided by cohfluent fiuid administration combined with
   diuretics． Therefore， this drug seemed relatively safe to be administered to any case in this respect．
   However， administration of this drug to aged patients was hindered ipy rather severe gastrointestinal
   symptoms．
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Cases Primary tumorMetastaslsT．N．M． Stage Prevloustreatment
Case l N，K． ｝6 M
Case 2 K．T． 22 M
Case 5 N．O． 51M
Case 4 M，T， 51M
Cose 5 T．A． 82M
Case 6 H．A 77M
Case 7 H．K， 80日
目ase 8 Y．T． 65M
Case 9 T． T， 62 M
Cose lO S．N． 72M
Cosell MM． 59M
Testi＄
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            CDDP ： cisp［otin 25 mg／day
            VBL ： vinbiastine 10mgldoy
            BLM：b［eomycin 15mglday
Fig・2・睾丸腫瘍患者に対するcisplatinの投与方法
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25 mg （ 1 4 mgfm2）
25mg ｛ ［7mg／m2）
55mg （ 30 mg／m2 ）
50mg （ 37 mg／m2 ｝ ＊
50mg（37 mg／m21＊
50mg C 50mg／m2）
50mg （ 52 mg／m2 ）
50 mg （ 32 mg／m2） ＊
50 g （31 mg／m2）
550mg （ 224 rng／m2）
575mg（217mgfm2］
550mg ｛ 232 mg／m2）
3［5mg｛267 mg／m2 i
500mg（222mg／m2）＊
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Koyama ＆ Saito’s criteria
   compiete response （CR）
   partio］ response C PR｝
   minor response i MR）
   no chonge （ NC）
   proqressive disease ｛PD）








      I－C
      I－B
      ［一A
      o－c
      O－B
      O－A
      o－o






























Group 工  Group工1
G工十〇xicify      3   ／4   7【2＊｝／7
hepa†〇十〇xicity    l   ／4  1＊ ！7
myelosuppression 1 ／4 2 ／7
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